tbuckley/cabot-search huggingface dataset:
Identification of prostate cancer-expressed microRNAs associated with clinical recurrence (cR) and prostate cancer-specific survival (PCSS) following radical prostatectomy (RP).
Authors: Eric A. Klein, Mike Kiefer, Michael Crager, Cristina Magi-Galluzzi, Sara Moscovita Falzarano, Robert J. Pelham, Carl Millward, Diana B. Cherbavaz, Joffre Baker, Steven Shak, Mark Lee
Journal: Journal of Clinical Oncology (2012)

21 Background: We previously identified messenger RNAs (mRNAs) whose expression can distinguish aggressive from indolent prostate cancer. Representing multiple key genomic pathways, these mRNAs are significantly associated with cR and PCSS after RP, providing prognostic information beyond PSA, cT stage and Gleason Score. We evaluated microRNA expression in the same specimens for association with cR and PCSS. Methods: All cT1/cT2 prostate cancer pts treated with RP at Cleveland Clinic from 1987-2004 were identified (n~2,600), of which 127 pts w/ cR and 374 pts w/o cR after RP were randomly selected using cohort sampling. RNA was purified from 2 macrodissected FPE tumor specimens per pt. Expression of 76 test and 5 reference microRNAs was quantified by RT-PCR. Cox regression and control of the false discovery rate (FDR) was used to assess reference-normalized microRNA and mRNA expression for association with cR and PCSS. Results: 106 pts with cR and 310 without cR had sufficient RNA and successful microRNA assays. Analysis of primary Gleason pattern tumor tissue for each pt identified 21 microRNAs associated with cR and 13 microRNAs associated with PCSS, with FDR at 10%; 8 microRNAs were associated with both endpoints. Similar analysis of highest Gleason pattern tumor tissue for each pt identified 22 microRNAs associated with cR (17 overlapping with those for the primary Gleason pattern) and 7 microRNAs associated with PCSS, with FDR at 10%; 4 were associated with both endpoints. miR-1, miR-21, miR-93, and miR-106b were associated with both cR and PCSS in primary and highest Gleason pattern specimens. The 76 microRNAs in this study tended to have weaker association with cR and PCSS than the 732 mRNAs. In multivariate analyses, mRNAs and microRNAs provided prognostic information beyond PSA, cT stage, and biopsy Gleason score. MicroRNAs co-express more frequently with each other than with mRNAs, which may indicate distinct biological regulation. Conclusions: Expression of some microRNAs assayed in FPE prostate tumor tissue was associated with cR and PCSS after RP in this study, and may retain prognostic value in the face of tumor heterogeneity.
Update in Combined Chelation Therapy with Deferoxamine and Deferiprone in Brazilian Patients with Thalassemia Major: Assessment of Three Years
Authors: Sandra Regina Loggetto, Mônica Veríssimo, Antônio Fabron Júnior, Giorgio Roberto Baldanzi, Nelson Hamerschlak, Juliano Lara Fernandes, Carmen Cunha Mello Rodrigues, Ana Cristina C. Villani França, Laércio Rosemberg, Alexandre Parma, Maria Luiza Petillo, Maria Odila J A Moura, Fabrício Biscaro Pereira, Edna Carboni, Sandra Saemi Nakashima
Journal: Blood (2008)
Molecular types and prognostic markers uPA/PAI-1 for 2,497 early breast cancer patients in the multicenter, randomized NNBC 3-Europe trial.
Authors: E. J. Kantelhardt, C. Thomssen, M. Vetter, C. Meisner, M. Schmidt, P. Martin, F. Sweep, G. Von Minckwitz, M. Schmitt, N. Harbeck
Journal: Journal of Clinical Oncology (2010)

10539 Background: The ASCO guidelines recommend the validated invasion markers uPA/PAI-1 (Harris, JCO 2007) for routine risk assessment in N0 breast cancer. Also, St.Gallen-adapted clinico-pathological algorithm (CP) (Schmidt, Ann Oncol 2009) is widely used. Other molecular prognostic markers are currently evaluated in prospective trials; results are pending. Methods: From Dec 2002 to Jan 2009, 153 centers recruited 4,149 patients (pts). Risk assessment was performed by CP or by an uPA/PAI-1 based algorithm (UP). For UP, G1 tumors were considered low-risk, and pts <35y or G3 tumors were considered high-risk. Risk assessment in G2 was performed according to uPA/PAI-1 tumor concentrations (ELISA). This exploratory analysis describes the distribution of pts characteristics as well as molecular types of pts assessed by UP (n=2,497). Results: Pts characteristics were distributed as expected: G1 (17,3%), G2 (52%), G3 (31,2%); <35y (1.7%); T1 (70.6%); ER and PR neg (16.9%); HER2 +++ (13.2%). uPA/PAI-1 values were available for G1-tumors in 81%, for G2 in 99.5%, and G3 in 84%, respectively (in total, 8% missing values). Here we describe distributions of uPA/PAI-1 values, and UP risk assessment compared to the St. Gallen-adapted risk assessment in different molecular types assessed by IHC (ER, PR, HER2) (Table). Conclusions: UP-assessment reveals discordant results from CP-assessment, in particular regarding luminal tumors. In addition, some triple-negative tumors were assessed low risk by UP. Thus, UP-assessment adds to clinico-pathological risk assessment and tumors with discordant assessment will need further characterization. Outcome results of NNBC-3 Europe will show whether discordances are clinically meaningful. No. of pts Low uPA/PAI- 1 Low UP High risk by CP => low risk by UP Low risk by CP => high risk by UP Risk CP = UP N.A. (% of total) (% of molecular type) Luminal 1,783 (71) 701 (39) 882 (50) 203 (11) 357 (20) 1,221 (69) 2 Luminal HER2 85 (3) 16 (19) 1 (1) 1 (1) 0 84 (99) 0 HER2 336 (14) 43 (13) 15 (4) 15 (4) 0 321 (95) 0 Triple-negative 242 (10) 58 (24) 44 (18) 44 (18) 0 198 (82) 0 N.A. 51 (2) 24 (47) 25 (49) 6 (12) 0 18 (35) 27 N (%) of total 2,497 (100) 842 (36) 967 (23) 269 (11) 357 (14) 1,842 (74) 29 No significant financial relationships to disclose.
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death
Authors: Eli Muchtar, Morie A. Gertz, Shaji K. Kumar, Martha Q. Lacy, David Dingli, Francis K. Buadi, Martha Grogan, Suzanne R. Hayman, Prashant Kapoor, Nelson Leung, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Wilson Gonsalves, Rahma Warsame, Taxiarchis V. Kourelis, Stephen Russell, John A. Lust, Yi Lin, Ronald S. Go, Steven Zeldenrust, Robert A. Kyle, S. Vincent Rajkumar, Angela Dispenzieri
Journal: Blood (2017)
Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma
Authors: James E McDonald, Marcus M Kessler, Michael Gardner, Amy Buros, Sarah Waheed, James Ntambi, Frits van Rhee, Maurizio Zangari, Christoph Heuck, Nathan Petty, Carolina Schinke, Sharmilan Thanendrarajan, Alan Mitchell, Antje Hoering, Bart Barlogie, Gareth J Morgan, Faith E Davies
Journal: Blood (2015)
Screening for Obstructive Sleep Apnea
Authors: Sachin R. Pendharkar, Fiona M. Clement
Journal: JAMA Internal Medicine (2017)

Daniel E. Jonas, MD, MPH; Halle R. Amick, MSPH; Cynthia Feltner, MD, MPH; Rachel Palmieri Weber, PhD; Marina Arvanitis, MD, MPH; Alexander Stine, BA; Linda Lux, MPA; Russell P. Harris, MD, MPH
Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial
Authors: H Demeyer, Z Louvaris, A Frei, R A Rabinovich, C de Jong, E Gimeno-Santos, M Loeckx, S C Buttery, N Rubio, T Van der Molen, N S Hopkinson, I Vogiatzis, M A Puhan, J Garcia-Aymerich, M I Polkey, T Troosters
Journal: Thorax (2017)

<h3>Rationale</h3> Reduced physical activity (PA) in patients with COPD is associated with a poor prognosis. Increasing PA is a key therapeutic target, but thus far few strategies have been found effective in this patient group. <h3>Objectives</h3> To investigate the effectiveness of a 12-week semiautomated telecoaching intervention on PA in patients with COPD in a multicentre European randomised controlled trial. <h3>Methods</h3> 343 patients from six centres, encompassing a wide spectrum of disease severity, were randomly allocated to either a usual care group (UCG) or a telecoaching intervention group (IG) between June and December 2014. This 12-week intervention included an exercise booklet and a step counter providing feedback both directly and via a dedicated smartphone application. The latter provided an individualised daily activity goal (steps) revised weekly and text messages as well as allowing occasional telephone contacts with investigators. PA was measured using accelerometry during 1 week preceding randomisation and during week 12. Secondary outcomes included exercise capacity and health status. Analyses were based on modified intention to treat. <h3>Main results</h3> Both groups were comparable at baseline in terms of factors influencing PA. At 12 weeks, the intervention yielded a between-group difference of mean, 95% CI (lower limit – upper limit; ll-ul) +1469, 95% CI (971 to 1965) steps/day and +10.4, 95% CI (6.1 to 14.7) min/day moderate PA; favouring the IG (all p≤0.001). The change in 6-min walk distance was significantly different (13.4, 95% CI (3.40 to 23.5) m, p&lt;0.01), favouring the IG. In IG patients, an improvement could be observed in the functional state domain of the clinical COPD questionnaire (p=0.03) compared with UCG. Other health status outcomes did not differ. <h3>Conclusions</h3> The amount and intensity of PA can be significantly increased in patients with COPD using a 12-week semiautomated telecoaching intervention including a step counter and an application installed on a smartphone. <h3>Trial registration number:</h3> NCT02158065.
The Obligate Role of TAK1 in the Survival of Hematopoietic Stem Cells and Progenitors in Mice.
Authors: Minghui Tang, Zhenbiao Xia, Shubin Zhang, Shanshan Zhang, Xudong Wei, Peter Breslin, Wei Wei, Manuel Diaz, Shizuo Akira, Jiwang Zhang
Journal: Blood (2007)
AML Survival and In Vivo Progression Is Dependent On β-Catenin Signaling.
Authors: Elena K Siapati, Magda Papadaki, Zoi Kozaou, Erasmia Rouka, Evridiki Michali, Dimitrios Gogos, Ioanna Savvidou, Despoina S Kyriakou, Nikolaos.I. Anagnostopoulos, George Vassilopoulos
Journal: Blood (2009)
A JAK2-V617F Activating Mutation in Addition to C-KIT and FLT3 Mutations Is Associated with Clinical Outcome in Patients with t(8;21)(q22;q22;) Acute Myeloid Leukemia.
Authors: Tomoko Nanri, Eisaku Iwanaga, Naofumi Matsuno, Toshiro Kawakita, Hitoshi Suzushima, Fumio Kawano, Hiroaki Mitsuya, Norio Asou
Journal: Blood (2007)
The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs),
Authors: Ajay K. Nooka, Jonathan L. Kaufman, Madhusmita Behera, Charise Gleason, Amelia Langston, Conor Ermst Steuer, Christopher R Flowers, Lawrence H. Boise, Sagar Lonial
Journal: Blood (2011)
Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse.
Authors: Frederick Pimm, Richard Szydlo, Letizia Foroni, Francesco Dazzi, Jaspal S Kaeda, Gareth Gerrard, Alistair Reid, Mikel Valganon, Edward J Kanfer, John M Goldman, Dragana Milojkovic, David Marin, Jane Apperley
Journal: Blood (2012)
Minimal Residual Disease (MRD) after Frontline Therapy in Adolescent and Young Adult (AYA) Patients with Acute Lymphoblastic Leukemia (ALL) Treated on Two Separate Regimens.
Authors: Michael Rytting, Deborah Thomas, Jeffrey Jorgensen, Hagop Kantarjian, Rebecca Garris, Brenda Muriera, Susan O’Brien
Journal: Blood (2007)
Effect of <i>KRAS</i> mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases.
Authors: Georgios A Margonis, Gaya Spolverato, Yuhree Kim, Georgios Karagkounis, Michael A. Choti, Timothy M. Pawlik
Journal: Journal of Clinical Oncology (2015)

282 Background: The impact of KRAS mutation on overall (OS) and recurrence-free (RFS) survival of patients with colorectal liver metastases (CLM) remains poorly defined. We sought to investigate the prognostic value of KRAS in a large cohort of patients undergoing liver resection for CLM. Methods: Between 2003 and 2013, 334 patients underwent hepatic resection for CLM at Johns Hopkins Hospital and met the inclusion criteria. Somatic mutations at codons 12/13 were evaluated through a sequencing analysis of the tumor samples. Clinicopathological characteristics, perioperative details, and outcomes were stratified by KRAS status (mtKRAS vs. wtKRAS) and analyzed. Results: Among 334 patients undergoing liver resection for CLM, mtKRAS was identified in 115 (34.4%) patients. Median CEA was 7.3 ng/dL; 40.4% of patients had a solitary tumor and median tumor size was 2.5 cm. At a median follow-up of 28.2 months, recurrence was observed in 59 (51.3%) patients with mtKRAS and 117 (53.4%) patients with wtKRAS (P=0.71); there was no difference in the pattern of recurrence (liver: mtKRAS, 39.0% vs. wtKRAS, 52.1%; lung: mtKRAS, 55.6% vs. wtKRAS, 64.3%; both P&gt;0.05). While 5-year log-rank OS was comparable among mtKRAS (41.6%) vs. wtKRAS (48.5%), on multivariable Cox survival analysis mtKRAS was associated with worse OS(HR, 1.65; 95%CI, 1.07-2.54). Moreover, among patients who experienced a recurrence, 5-year OS was worse among those patients who had mtKRAS (mtKRAS, 28.1% vs. wtKRAS, 44.5%; P=0.004). After controlling for tumor factors, as well as receipt of chemotherapy, mtKRAS status remained independently associated with a worse outcome among patients who recurred(HR 2.07, 95% CI 1.31-3.27; P=0.002). Conclusions: mtKRAS was noted in one-third of patients with CLM. While KRAS status did not impact pattern of recurrence, mtKRAS was an independent predictor of worse OS among patients who experienced a recurrence following resection of CLM.
Myeloid Nuclear Differentiation Antigen (MNDA) Protein Expression in Myelodysplastic Syndrome (MDS) Is Reduced in Maturing Myeloid Cells.
Authors: Keith Shults, David R. Head, Leanne Flye, Madan H. Jagasia, Stacey A. Goodman, Sara A. McClintock-Treep, Fouad I. Boulos, James W. Jacobberger, Greg Stelzer, Robert C. Briggs
Journal: Blood (2004)
Systemically Administered Hydrocortisone Exerts Differential Effects on B and T Lymphocytes and Natural Killer Cells in Healthy Donors
Authors: Matthew J. Olnes, Angelique Biancotto, Ena Wang, Robert Reger, Shira Perl, Howard Dickler, J. Philip McCoy, Francesco Marincola, Richard Childs, Neal S. Young
Journal: Blood (2011)
Allogeneic Stem Cell Transplantation for Accelerated/Blastic Phase Philadelphia-Chromosome Negative MPN
Authors: Anjum Bashir Khan, Donal McLornan, Yogesh Jethava, Kavita Raj, Victoria T Potter, Hugues de Lavallade, Majid A Kazmi, ZiYi Lim, Judith C. W. Marsh, Sangeeta Atwal, Victor Noriega, Claire N Harrison, Antonio Pagliuca, Ghulam J. Mufti
Journal: Blood (2012)
Tumor burden as an independent prognostic factor in metastatic renal cell carcinoma (mRCC).
Authors: Bernard J. Escudier, Roberto Iacovelli, Emilie Lanoy, Laurence Albiges, Karim Fizazi
Journal: Journal of Clinical Oncology (2012)

397 Background: During the last ten years, several classifications have been used to assess the prognosis in mRCC. In none of them, tumor burden (TB) has been considered. This study investigates the prognostic role of baseline TB in terms of progression free survival (PFS) and overall survival (OS), in patients with mRCC. Methods: All patients with clear cell mRCC enrolled in our center, in 2 second-line trials, post cytokine, with sunitinib and sorafenib or placebo (Escudier JCO 2009, Escudier NEJM 2007), were selected for this analysis. TB was defined as the sum of the longest unidimensional diameter of each target lesions assessed using RECIST criteria. PFS and OS were estimated using Kaplan-Meier method and compared using the log-rank test. Association between TB and PFS or OS was evaluated using the Cox proportional hazards model. Multivariable analyses were adjusted for modified MSKCC risk class and treatment. Non-parametric Spearman rank test (r s ) was used to assess the correlations between TB and MSKCC risk groups or ECOG Performance Status (PS). Results: Final population included 124 patients: 66% received sorafenib or sunitinib and 34% received placebo; median follow up was 80.1 months (IQR: 68.8 – 88.0). Baseline TB was divided into 3 tertiles (1.3 - 9.4 cm; 9.5 - 19.0 cm; 19.1 - 47.3 cm). TB was related to PFS and OS and, when adjusting for modified MSKCC risk class and treatment, these associations remained significant: each 1 cm increase in TB increased the progression risk by 5% (HR: 1.05; 95%CI, 1.02 – 1.07; p &lt; 0.0001) and the death risk by 5% (HR: 1.05; 95%CI, 1.03 – 1.08; p &lt; 0.0001). OS decreased with TB: the median tertiles OS values were: 42.1 months (95%CI: 24.0 – 60.2), 20.1 months (95%CI: 14.5 – 25.7), and 11.2 months (95%CI: 4.8 – 17.6), respectively (p &lt; 0.0001, figure 2). The TB was positively related to ECOG PS (r s = 0.357; p &lt; 0.0001) and to MSKCC risk score (r s = 0.478; p &lt; 0.0001). Patients with higher TB had shorter PFS, shorter OS, poorer MSKCC score and increased ECOG PS. Conclusions: TB is easy to calculate with standard CT and significantly relates to OS and PFS in patients with mRCC. We report for the first time the independent prognostic role of baseline TB in mRCC.
Impaired Immune Reconstitution after Cord Blood Transplantation in Adults Is Associated with Delayed Recovery but Not Functional Impairment of CD8+T Cells.
Authors: Julia Brown, Karen Ballen, Sean McDonough, Xupeng Ge, Kristen Stevenson, Haesook Kim, Carol Reynolds, Bimalangshu R. Dey, Steve McAfee, Eyal Attar, Thomas Spitzer, Corey Cutler, Vincent Ho, Edwin Alyea, Robert Soiffer, Joseph H. Antin, Jerome Ritz, Vassiliki A. Boussiotis
Journal: Blood (2007)
Reply
Authors: Juan G. Abraldes, Annalisa Berzigotti
Journal: Hepatology (2017)

Potential conflict of interest: Nothing to report. REPLY: We thank Dr. Giannini and Dr. Savarino for their interest in our study. They highlight the fact that liver stiffness measurements by transient elastography (LSM by TE) have a non‐negligible rate of failures. In those cases, two of the three models that we tested in our study (LSPS and a combination of platelet count and LSM by TE) would not be applicable, whereas the other proposed model, platelet‐to‐spleen ratio (PSR; which includes platelet count and the bipolar diameter of the spleen, first proposed by Dr. Giannini and colleagues) would be always applicable, given that spleen diameter can be measured in 100% of the cases. Indeed, one of the aims of the ANTICIPATE study was to provide different noninvasive tools to predict varices needing treatment, so that in case of failure or unavailability of one tool, an alternative tool could be used. This was done having in mind that the availability of LSM by TE is very limited in some areas of the world. The main conclusion of our study was that "LSPS, a combination of LSM by TE‐platelet count, or PSR could be used to identify a relevant subset of patients with compensated cirrhosis and Child‐Pugh A with a very low probability of VNT (<5%) in which endoscopy could be avoided." Therefore, we think we sufficiently addressed this concern in our report. The second issue raised by Drs. Giannini and Savarino was that the results of our study should be corrected in an "intention‐to‐test" analysis, taking into account the technical failures. This is especially important when using traditional measurements of diagnostic performance, such as sensitivity, specificity, and positive and negative predictive values. The approach that we followed in our study was, however, different. We used risk prediction modeling to assign a probability of the target condition for each value of the noninvasive predictor. The model (or its nomogram) can be used if the predictors are available and cannot be used if they are not. The performance statistics of the model only apply to the group of patients in which the model can be applied. Our approach therefore overcomes the question of how to factor technical failures on diagnostic accuracy parameters. The only value reported in our study that could be impacted by the rate of technical failures would be the percentage of endoscopies that would be avoided by a certain noninvasive test. Because our study was a blend of prospective and retrospective data, we cannot provide an exact applicability figure for our models. In a theoretical worst‐case scenario of 20% unreliable results/technical failures of LSM by TE, the number of endoscopies saved would decrease from 30% to 24%.
Altered lung structure and function in mid-childhood survivors of very preterm birth
Authors: Shannon J Simpson, Karla M Logie, Christopher A O'Dea, Georgia L Banton, Conor Murray, Andrew C Wilson, J Jane Pillow, Graham L Hall
Journal: Thorax (2017)

<h3>Rationale</h3> Survivors of preterm birth are at risk of chronic and lifelong pulmonary disease. Follow-up data describing lung structure and function are scarce in children born preterm during the surfactant era. <h3>Objectives</h3> To obtain comprehensive data on lung structure and function in mid-childhood from survivors of preterm birth. We aimed to explore relationships between lung structure, lung function and respiratory morbidity as well as early life contributors to poorer childhood respiratory outcomes. <h3>Methods</h3> Lung function was tested at 9–11 years in children born at term (controls) and at ≤32 weeks gestation. Tests included spirometry, oscillatory mechanics, multiple breath nitrogen washout and diffusing capacity of the lung for carbon monoxide. Preterm children had CT of the chest and completed a respiratory symptoms questionnaire. <h3>Main results</h3> 58 controls and 163 preterm children (99 with bronchopulmonary dysplasia) participated. Preterm children exhibited pulmonary obstruction and hyperinflation as well as abnormal peripheral lung mechanics compared with term controls. FEV<sub>1</sub> was improved by 0.10 z-scores for every additional week of gestation (95% CI 0.028 to 0.182; p=0.008) and by 0.34 z-scores per z-score increase in birth weight (0.124 to 0.548; p=0.002). Structural lung changes were present in 92% of preterm children, with total CT score decreased by 0.64 (−0.99 to −0.29; p&lt;0.001) for each additional week of gestation. Obstruction was associated with increased subpleural opacities, bronchial wall thickening and hypoattenuated lung areas on inspiratory chest CT scans (p&lt;0.05). <h3>Conclusions</h3> Abnormal lung structure in mid-childhood resulting from preterm birth in the contemporary era has important functional consequences.
IGHV4-34 B-Cell Receptor Immunoglobulins from CLL Stereotyped Subset 4 React with Influenza A Virus: Requirement for IGHV-D-J/Iglv-J Rearrangement and Isotype Switching to IgG
Authors: Yun Liu, Rosa Catera, Florian Krammer, Chao Gao, Xiao-Jie Yan, Kanti R. Rai, Jacqueline C. Barrientos, Steven L. Allen, Jonathan E. Kolitz, Adolfo García-Sastre, Ten Feizi, Nicholas Chiorazzi
Journal: Blood (2014)
Epidemiology of Plasma Cell Disorders in a General Hospital: A Retrospective Study of 102 Patients.
Authors: Irene Ricca, Giacomo Tamponi, Celeste Arnò, Angelo Bosio, Flavio Cerrato, Marisa Coggiola, Giuseppe Epifani, Fiorella Giacometto, Gabriele Monaco, Ottavio Pallisco, Elisa Scalabrino, Loris Varvello, Carlo A. Raucci, Attilio Salomone, Claudio Pascale
Journal: Blood (2007)
Multicenter Retrospective Analysis of High Dose Chemotherapy and Autologous PBSCT for Ovarian Cancer.
Authors: Kyoung Ha Kim, Jong-Ho Won, Hee-Sook Park, Seong Hyun Jeong, Hyun Woo Lee, Joon Seong Park, Seok-Goo Cho, Joon Mo Lee, Chong Won Park, Dong Hwan (Dennis) Kim, Jun Ho Jang, Won Sik Lee, Jung Lim Lee, Yeung-Chul Mun, Chu-Myong Seong, Han Jo Kim
Journal: Blood (2009)